# P36504 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The P36504 gene encodes TEM-1 β-lactamase, a plasmid-borne enzyme that confers ampicillin resistance in Gram-negative bacteria by hydrolyzing the β-lactam ring of penicillins and early cephalosporins.
- TEM-1 is the precursor to over 200 Extended-Spectrum β-Lactamase (ESBL) variants, such as TEM-3 and TEM-4, which arise from specific amino acid substitutions (e.g., G238S, E104K) that expand the active site to hydrolyze oxyimino-cephalosporins.
- Clinical detection of ESBL-producing organisms relies on phenotypic screening for reduced susceptibility to ceftazidime or cefotaxime, confirmed by synergy testing with β-lactamase inhibitors like clavulanic acid.
- Infections caused by ESBL-producing bacteria are associated with significantly increased mortality rates (20-40%) and prolonged hospital stays, necessitating prompt and accurate diagnosis for effective treatment.
- β-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam) are co-administered with β-lactam antibiotics to neutralize TEM-1 activity, though inhibitor-resistant TEM (IRT) variants can emerge.
- Next-generation inhibitors like avibactam and vaborbactam offer broader coverage against TEM ESBLs and other challenging β-lactamases, representing crucial therapeutic advancements.

---

## Executive Summary & Key Metadata

The UniProt accession **P36504** corresponds to the **TEM-1 β-lactamase** (also known as class A β-lactamase, penicillinase, or blaTEM-1), a monomeric 29-kDa serine hydrolase encoded by the *blaTEM-1* gene. This enzyme is the archetypal plasmid-borne extended-spectrum β-lactamase (ESBL) precursor and remains the most prevalent mechanism of ampicillin resistance in Gram-negative bacteria, particularly *Escherichia coli* and *Klebsiella pneumoniae*. TEM-1 hydrolyzes the β-lactam ring of penicillins and early cephalosporins, rendering them therapeutically inert. Its clinical significance is profound: mutations in *blaTEM-1* produce TEM-2, TEM-3, and over 200 TEM-type ESBL variants that confer resistance to oxyimino-cephalosporins (e.g., ceftazidime, cefotaxime) and are inhibited by clavulanic acid, sulbactam, and tazobactam.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | P36504 (UniProt ID; gene: *blaTEM-1*) |
| **UniProt Accession** | P36504 |
| **Representative PDB ID** | 1BTL (TEM-1 with benzylpenicillin), 1M40 (TEM-1 with tazobactam), 1XPB (TEM-1 E166A mutant) |
| **Chromosomal Locus** | Plasmid-borne (Tn3 transposon); chromosomal homologs in *E. coli* K12 (ampC is distinct) |
| **Primary Molecular Function** | Serine-type β-lactamase (EC 3.5.2.6); hydrolyzes β-lactam antibiotics |
| **Disease & Pathology Associations** | Antimicrobial resistance (AMR); ESBL-mediated multidrug resistance; community- and hospital-acquired infections |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Genetic Context and Mobilization

The *blaTEM-1* gene is not a chromosomal housekeeping gene in most Enterobacterales; it resides on **transposon Tn3** (4957 bp), which is frequently embedded within larger conjugative plasmids (e.g., pBR322, pUC19, R-factor RP4). Tn3 consists of a transposase gene (*tnpA*), a resolvase gene (*tnpR*), and the *blaTEM-1* gene flanked by 38-bp inverted repeats. The entire transposon can mobilize between replicons via a replicative "copy-and-paste" mechanism, which explains the rapid horizontal dissemination of ampicillin resistance across Gram-negative pathogens.

In the reference plasmid pBR322, the *blaTEM-1* open reading frame spans nucleotides 4153 to 5013 (861 bp), encoding a 286-amino-acid precursor protein. A 23-residue N-terminal signal peptide is cleaved during Sec-dependent translocation to the periplasm, yielding the mature 263-residue enzyme (molecular weight 28,900 Da). The mature protein lacks post-translational modifications other than the formation of two disulfide bonds (Cys77–Cys123 and Cys168–Cys238, Ambler numbering).

### 1.2 Promoter Architecture and Transcriptional Regulation

The *blaTEM-1* promoter is exceptionally strong and constitutive. Two overlapping promoters, **Pa** and **Pb**, drive transcription in pBR322. The Pa promoter (TTGACA at −35, TATAAT at −10) is recognized by the housekeeping sigma factor σ70 (RpoD). The Pb promoter is weaker and oriented in the opposite direction, contributing to basal expression. Transcriptional attenuation is minimal; mRNA stability is high (half-life > 10 min), and translation is efficient due to a strong Shine-Dalgarno sequence (AGGAGG) located 7 nucleotides upstream of the start codon.

Regulation is primarily **substrate-inducible** in some contexts, but TEM-1 is largely considered constitutively expressed. However, in clinical isolates, promoter-up mutations (e.g., a G-to-T transversion at position −10) can increase β-lactamase production 5- to 20-fold, leading to high-level resistance even to β-lactamase inhibitors. This promoter polymorphism is a known contributor to the "inoculum effect" observed in ESBL-producing infections.

### 1.3 Isoforms and Variants

The *blaTEM-1* gene does not undergo alternative splicing (prokaryotic), but **protein isoforms** arise from post-translational processing and point mutations:

- **TEM-1 (wild-type)**: The canonical enzyme with a pI of 5.4.
- **TEM-2**: A single amino acid substitution (Gln39Lys in the mature protein) that changes the pI to 5.6 but does not alter substrate profile.
- **TEM-3 to TEM-200+**: ESBL variants with one to five amino acid substitutions, most commonly at positions 104 (Glu→Lys), 164 (Arg→Ser/His/Cys), 238 (Gly→Ser), and 240 (Glu→Lys). These substitutions expand the active-site cavity to accommodate oxyimino-cephalosporins.

The **Ambler numbering system** (based on the mature TEM-1 sequence) is universally used to describe mutations. For example, the clinically critical substitution **Gly238Ser** (G238S) is located in the Ω-loop, a conserved structural element that positions the catalytic Ser70.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold

TEM-1 belongs to the **class A β-lactamase family** (SCOP: Alpha/Beta class; fold: β-lactamase/transpeptidase-like). The mature enzyme adopts a two-domain architecture:

1. **All-α domain** (residues 1–60 and 235–263): A bundle of five α-helices (H1, H2, H8, H9, H10) that forms the back wall of the active site.
2. **α/β domain** (residues 61–234): A five-stranded antiparallel β-sheet (S1–S5) flanked by three α-helices (H3, H4, H5) and the Ω-loop (residues 161–179).

The active site is located at the interface of these domains, forming a deep groove that accommodates the β-lactam substrate.

### 2.2 Catalytic Machinery

The catalytic mechanism is a two-step serine acylation/deacylation process:

- **Ser70** (nucleophile): Attacks the β-lactam carbonyl carbon.
- **Lys73** and **Glu166**: Act as general base/acid catalysts. Glu166 abstracts a proton from the hydrolytic water molecule during deacylation.
- **Ser130** and **Asn132**: Stabilize the oxyanion tetrahedral intermediate via hydrogen bonding.
- **Lys234**: Forms a salt bridge with the carboxylate group of the β-lactam substrate.

The **Ω-loop** (residues 161–179) contains the conserved motif **SDN** (Ser130-Asp131-Asn132) and the catalytic Glu166. Mutations in this loop (e.g., Arg164Ser) disrupt the hydrogen-bonding network, altering substrate specificity and conferring ESBL activity.

### 2.3 Disulfide Bonds and Structural Stability

Two disulfide bonds (Cys77–Cys123 and Cys168–Cys238) stabilize the α/β domain and the Ω-loop. Reduction of these bonds (e.g., by dithiothreitol in vitro) leads to rapid thermal denaturation (Tm drops from 52°C to 38°C). The Cys168–Cys238 bond is particularly critical for maintaining the conformation of the Ω-loop; its disruption is lethal to enzyme function.

### 2.4 Structural Dynamics and Substrate Promiscuity

Molecular dynamics simulations reveal that TEM-1 undergoes significant conformational sampling. The Ω-loop toggles between "open" and "closed" states, controlling access to the active site. The enzyme's catalytic efficiency (kcat/Km) for benzylpenicillin is ~1 × 10^8 M⁻¹ s⁻¹, approaching the diffusion limit. For ampicillin, kcat/Km is ~5 × 10^7 M⁻¹ s⁻¹, and for cephalothin, ~1 × 10^6 M⁻¹ s⁻¹.

The **G238S mutation** (found in TEM-3 and many ESBLs) enlarges the active-site cavity by ~30 ų, allowing the bulky oxyimino side chains of ceftazidime and cefotaxime to enter. However, this gain-of-function comes at a cost: reduced catalytic efficiency for penicillins and increased susceptibility to β-lactamase inhibitors (clavulanate, tazobactam).

### 2.5 Interactive 3D Visualizer

For a hands-on exploration of the TEM-1 structure, including the catalytic triad, Ω-loop, and inhibitor-binding pockets, use the interactive visualizer:

[Interactive 3D Protein Visualizer: Load P36504 (PDB: 1BTL)](/tools/protein-structure-viewer?source=alphafold&accession=P36504)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Enzymatic Mechanism

TEM-1 is a **serine β-lactamase** that hydrolyzes the amide bond of the β-lactam ring. The reaction proceeds via:

1. **Pre-acylation**: Substrate binding positions the β-lactam carbonyl in the oxyanion hole (formed by Ser70 backbone amide and Asn132 side chain).
2. **Acylation**: Ser70's hydroxyl attacks the carbonyl carbon, forming a tetrahedral intermediate stabilized by the oxyanion hole. Lys73 acts as a general base, abstracting the Ser70 hydroxyl proton. The C–N bond of the β-lactam ring is cleaved, yielding a covalent acyl-enzyme intermediate.
3. **Deacylation**: A water molecule, activated by Glu166, attacks the acyl-enzyme intermediate. The ester bond is hydrolyzed, regenerating the free enzyme and releasing the ring-opened, biologically inactive product.

The overall reaction is:

**β-lactam + H₂O → β-lactam (ring-opened) + H⁺**

### 3.2 Interaction with the Bacterial Cell Envelope

In Gram-negative bacteria, TEM-1 is secreted into the **periplasmic space** via the Sec pathway. The signal peptide is cleaved by signal peptidase I (LepB). Once in the periplasm, the enzyme encounters antibiotics that have diffused through outer membrane porins (OmpF/OmpC). The enzyme's location is strategic: it hydrolyzes antibiotics before they reach their target, the penicillin-binding proteins (PBPs) on the inner membrane.

### 3.3 Protein-Protein Interaction Network

TEM-1 has few known protein-protein interactions in its native bacterial host. However, in the context of **phage display** and **two-hybrid systems**, TEM-1 has been engineered as a reporter enzyme. Its interaction with the **periplasmic chaperone SurA** and the **disulfide bond oxidoreductase DsbA** is essential for proper folding and disulfide bond formation. In the absence of DsbA, TEM-1 misfolds and aggregates, leading to a 10-fold reduction in activity.

### 3.4 Evolutionary Dynamics and Fitness Costs

The acquisition of *blaTEM-1* imposes a fitness cost on the host bacterium due to the metabolic burden of protein overexpression. However, this cost is mitigated by:

- **Promoter downregulation** in some plasmids.
- **Gene amplification** under antibiotic pressure.
- **Compensatory mutations** in the host genome (e.g., in *ompF* or *marR*).

The evolutionary trajectory of TEM-1 toward ESBL activity is a textbook example of **adaptive protein evolution**. Directed evolution experiments (e.g., by Palzkill and colleagues) have shown that the path to cefotaxime resistance requires at least two mutations (e.g., G238S + E104K), which act synergistically to expand substrate specificity while maintaining structural stability.

### 3.5 Mermaid Diagram: TEM-1-Mediated Resistance Pathway

```mermaid
flowchart TD
    A["Antibiotic (e.g., Ampicillin)"] -->|"Diffusion"| B["Outer Membrane Porin OmpF"]
    B --> C["Periplasm"]
    C --> D{"TEM-1 β-lactamase"}
    D -->|"Hydrolysis"| E["Inactive Ring-Opened Product"]
    C -->|"Penetration"| F["Inner Membrane"]
    F --> G["Penicillin-Binding Proteins"]
    G -->|"Inhibition"| H["Cell Wall Synthesis Blocked"]
    E --> I["No Antibacterial Effect"]
    D -->|"Mutation G238S"| J["ESBL Variant"]
    J -->|"Hydrolysis of Cephalosporins"| K["Resistance to 3rd Gen Cephalosporins"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Classification of TEM Variants

The TEM family comprises over 200 named variants. They are classified into three functional groups:

1. **TEM-1/TEM-2 (wild-type)**: Narrow-spectrum; hydrolyze penicillins and early cephalosporins (cephaloridine, cephalothin). Inhibited by clavulanic acid.
2. **TEM ESBLs (TEM-3 to TEM-200+)**: Hydrolyze oxyimino-cephalosporins (cefotaxime, ceftazidime, ceftriaxone) and monobactams (aztreonam). Inhibited by clavulanic acid, sulbactam, and tazobactam.
3. **Inhibitor-Resistant TEM (IRT)**: Mutations that reduce inhibitor binding (e.g., Met69Leu, Arg244Ser) while retaining penicillinase activity. These variants are resistant to clavulanic acid but remain susceptible to penicillins.

### 4.2 Key Amino Acid Substitution Hotspots

| Position (Ambler) | Wild-Type Residue | Common Substitutions | Functional Consequence |
|---|---|---|---|
| 69 | Met | Leu, Ile, Val | Reduced inhibitor binding (IRT phenotype) |
| 104 | Glu | Lys | Enhanced cefotaxime hydrolysis |
| 164 | Arg | Ser, His, Cys | Disrupts Ω-loop; ESBL activity |
| 238 | Gly | Ser | Expands active site; ESBL activity |
| 240 | Glu | Lys | Enhanced ceftazidime hydrolysis |
| 244 | Arg | Ser, Cys | Reduced inhibitor binding |

### 4.3 Structural Basis of ESBL Mutations

- **G238S**: The Ser side chain forms a new hydrogen bond with the backbone carbonyl of Thr235, stabilizing the expanded active-site cavity. This mutation alone increases cefotaxime resistance 10-fold.
- **E104K**: The Lys side chain extends into the active site, forming a salt bridge with the carboxylate of the cephalosporin C-4 position. This mutation synergizes with G238S to produce high-level cefotaxime resistance (MIC > 256 μg/mL).
- **R164S**: The loss of the Arg guanidinium group disrupts a salt bridge with Asp179, increasing the flexibility of the Ω-loop. This allows the loop to accommodate bulkier cephalosporin side chains but reduces thermal stability by 5°C.

### 4.4 Clinical Phenotypes and Diagnostics

In clinical microbiology, ESBL-producing Enterobacterales are detected by:

- **Phenotypic screening**: Reduced susceptibility to ceftazidime (MIC ≥ 2 μg/mL) or cefotaxime (MIC ≥ 2 μg/mL).
- **Confirmation**: Synergy between clavulanic acid and ceftazidime/cefotaxime (double-disk synergy test).
- **Genotypic detection**: PCR amplification of *blaTEM*, *blaSHV*, and *blaCTX-M* genes, followed by Sanger sequencing or whole-genome sequencing.

Infections caused by ESBL-producing organisms are associated with:

- **Increased mortality** (30-day mortality: 20–40% vs. 10–15% for susceptible infections).
- **Longer hospital stays** (median +5 days).
- **Higher healthcare costs** (2- to 3-fold increase).

### 4.5 Differential Diagnosis

The presence of *blaTEM-1* does not automatically confer ESBL phenotype. Differential diagnoses include:

- **AmpC β-lactamases** (e.g., CMY-2, ACT-1): Resistant to cephalosporins but not inhibited by clavulanic acid.
- **Carbapenemases** (e.g., KPC, NDM, OXA-48): Hydrolyze carbapenems; often co-carried with *blaTEM*.
- **Hyperproduction of TEM-1**: Due to promoter mutations, can cause borderline cephalosporin resistance without ESBL mutations.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Context

TEM-1 is a bacterial enzyme; it does not directly interact with human host proteins. However, its presence in pathogenic bacteria shapes the host-pathogen interaction in several ways:

- **Microbiome perturbation**: Antibiotic treatment selects for TEM-1-producing commensals, which can serve as a reservoir for resistance genes.
- **Immune evasion**: The periplasmic location of TEM-1 does not directly modulate host immunity, but the resulting antibiotic resistance leads to prolonged infection, increased bacterial burden, and enhanced inflammatory responses.

### 5.2 Phage-Mediated Horizontal Gene Transfer

*blaTEM-1* is frequently mobilized by **generalized transduction** via bacteriophages. Phage particles can package plasmid DNA fragments containing *blaTEM-1* and transfer them to susceptible bacteria. This is particularly relevant in biofilms, where high phage density and bacterial proximity facilitate gene exchange.

### 5.3 Viral Interactions (Indirect)

In the context of **bacteriophage therapy**, TEM-1-producing bacteria are targeted by lytic phages. However, phages do not encode β-lactamases. Instead, some phages carry **endolysins** that degrade peptidoglycan, which can synergize with β-lactam antibiotics. The presence of TEM-1 does not affect phage replication but can influence the outcome of combined phage-antibiotic therapy.

### 5.4 Eukaryotic Host Response

The host immune system recognizes bacterial components (LPS, peptidoglycan) via TLR2 and TLR4. TEM-1 itself is not immunogenic in humans, but the inflammatory response to ESBL-producing infections is more severe due to delayed effective therapy. This leads to higher levels of pro-inflammatory cytokines (IL-6, TNF-α) and increased risk of sepsis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 β-Lactam Antibiotics (Substrates)

TEM-1 hydrolyzes a broad range of β-lactams:

| Drug Class | Examples | TEM-1 Susceptibility |
|---|---|---|
| Penicillins | Ampicillin, amoxicillin, piperacillin | High (hydrolyzed) |
| Cephalosporins (1st gen) | Cephalothin, cefazolin | Moderate |
| Cephalosporins (2nd gen) | Cefoxitin, cefuroxime | Low |
| Cephalosporins (3rd gen) | Ceftazidime, cefotaxime | Low (unless ESBL) |
| Carbapenems | Imipenem, meropenem | Very low (not hydrolyzed) |
| Monobactams | Aztreonam | Low (unless ESBL) |

### 6.2 β-Lactamase Inhibitors (BLIs)

Three clinically approved BLIs target TEM-1:

1. **Clavulanic acid** (co-amoxiclav): A mechanism-based "suicide" inhibitor. Forms a stable acyl-enzyme intermediate that slowly decarboxylates, leading to irreversible inactivation. However, IRT variants (e.g., Met69Leu) resist this inhibition.
2. **Sulbactam** (ampicillin-sulbactam): A penicillanic acid sulfone. Less potent than clavulanic acid but more stable.
3. **Tazobactam** (piperacillin-tazobactam): A more potent sulfone inhibitor. Effective against most TEM ESBLs but not IRTs.

### 6.3 Next-Generation Inhibitors

- **Avibactam** (ceftazidime-avibactam): A non-β-lactam diazabicyclooctane (DBO) inhibitor. Reversibly acylates Ser70 but is resistant to hydrolysis. Active against TEM ESBLs and KPC carbapenemases.
- **Vaborbactam** (meropenem-vaborbactam): A cyclic boronate inhibitor. Forms a covalent adduct with Ser70. Highly potent against TEM-1 (Ki = 0.008 μM).
- **Relebactam** (imipenem-cilastatin-relebactam): Similar to avibactam but with improved activity against AmpC.

### 6.4 Investigational Approaches

- **Monoclonal antibodies**: Anti-TEM-1 antibodies have been developed for diagnostic purposes (lateral flow assays) but not for therapeutic use.
- **CRISPR-Cas9**: Sequence-specific nucleases targeting *blaTEM-1* have been shown to re-sensitize bacteria to ampicillin in vitro. Delivery remains a challenge.
- **Antisense oligonucleotides**: Peptide nucleic acids (PNAs) complementary to the *blaTEM-1* mRNA can inhibit translation, but cellular uptake is poor.

### 6.5 Pharmacogenomic Considerations

The clinical efficacy of β-lactam/BLI combinations depends on:

- **Inoculum size**: High bacterial density (>10^7 CFU/mL) can overcome inhibitor concentrations, leading to treatment failure.
- **Mutation frequency**: The rate of emergence of IRT or ESBL mutations during therapy is ~10^-7 per generation.
- **Host factors**: Renal function affects drug clearance; dose adjustment is required for tazobactam and avibactam.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | Description |
|---|---|---|
| **UniProt** | P36504 | Primary protein sequence and annotation |
| **NCBI Gene** | 2806781 (blaTEM-1) | Gene records for TEM-1 |
| **NCBI Protein** | AAA23407.1 | TEM-1 protein sequence |
| **Ensembl Bacteria** | Not applicable (plasmid-borne) | Chromosomal context absent |
| **RCSB PDB** | 1BTL, 1M40, 1XPB | High-resolution crystal structures |
| **PDBsum** | 1BTL | Structural summaries and ligand interactions |
| **CATH** | 3.40.710.10 | Protein fold classification |
| **SCOP** | 56649 | Structural classification |
| **InterPro** | IPR000871 | β-lactamase class A family |
| **Pfam** | PF00144 | β-lactamase enzyme family |
| **STRING** | P36504 | Protein-protein interaction network |
| **BioGRID** | P36504 | Interaction data (minimal for bacterial proteins) |
| **ClinVar** | Not applicable | TEM-1 is not a human gene |
| **COG** | COG1680 | β-lactamase functional category |
| **KEGG** | K01467 | β-lactamase (EC 3.5.2.6) |
| **AMR databases** | CARD: TEM-1; ResFinder: blaTEM-1 | Antimicrobial resistance gene databases |
| **BLAST** | P36504 | Sequence similarity search |

### Gene Ontology (GO) Terms

| GO Term | Accession | Category | Description |
|---|---|---|---|
| β-lactamase activity | GO:0008800 | Molecular Function | Catalysis of β-lactam ring hydrolysis |
| Penicillin binding | GO:0008658 | Molecular Function | Binding to penicillin (substrate) |
| Periplasmic space | GO:0042597 | Cellular Component | Localization in the bacterial periplasm |
| Response to antibiotic | GO:0046677 | Biological Process | Cellular response to antibiotic exposure |
| Cell wall organization | GO:0007047 | Biological Process | Indirect role via PBP protection |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

The following references are cited in the text and provide the foundational literature for TEM-1 biology, structure, and clinical relevance.

1. **Ambler, R. P.** (1980). The structure of β-lactamases. *Philosophical Transactions of the Royal Society of London. B, Biological Sciences*, 289(1036), 321–331. https://doi.org/10.1098/rstb.1980.0049
   - Establishes the Ambler class A–D classification system for β-lactamases.

2. **Sutcliffe, J. G.** (1978). Nucleotide sequence of the ampicillin resistance gene of *Escherichia coli* plasmid pBR322. *Proceedings of the National Academy of Sciences*, 75(8), 3737–3741. https://doi.org/10.1073/pnas.75.8.3737
   - First complete DNA sequence of *blaTEM-1*.

3. **Jelsch, C., Mourey, L., Masson, J. M., & Samama, J. P.** (1993). Crystal structure of *Escherichia coli* TEM1 β-lactamase at 1.8 Å resolution. *Proteins: Structure, Function, and Bioinformatics*, 16(4), 364–383. https://doi.org/10.1002/prot.340160406
   - High-resolution structure of TEM-1.

4. **Strynadka, N. C., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K., & James, M. N.** (1992). Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 Å resolution. *Nature*, 359(6397), 700–705. https://doi.org/10.1038/359700a0
   - Structural basis of the acylation mechanism.

5. **Matagne, A., & Frère, J. M.** (1995). Contribution of mutant analysis to the understanding of enzyme catalysis: The case of class A β-lactamases. *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology*, 1246(2), 109–127. https://doi.org/10.1016/0167-4838(94)00191-6
   - Comprehensive review of TEM-1 mutational analysis.

6. **Palzkill, T., & Botstein, D.** (1992). Identification of amino acid substitutions that alter the substrate specificity of TEM-1 β-lactamase. *Journal of Bacteriology*, 174(16), 5237–5243. https://doi.org/10.1128/jb.174.16.5237-5243.1992
   - Directed evolution of TEM-1 toward ESBL activity.

7. **Bush, K., & Jacoby, G. A.** (2010). Updated functional classification of β-lactamases. *Antimicrobial Agents and Chemotherapy*, 54(3), 969–976. https://doi.org/10.1128/AAC.01009-09
   - Modern classification scheme for β-lactamases including TEM variants.

8. **Cantón, R., & Coque, T. M.** (2006). The CTX-M β-lactamase pandemic. *Current Opinion in Microbiology*, 9(5), 466–475. https://doi.org/10.1016/j.mib.2006.08.011
   - Contextualizes TEM-1 within the broader ESBL pandemic.

9. **Drawz, S. M., & Bonomo, R. A.** (2010). Three decades of β-lactamase inhibitors. *Clinical Microbiology Reviews*, 23(1), 160–201. https://doi.org/10.1128/CMR.00037-09
   - Comprehensive review of BLIs and their mechanisms.

10. **Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R. F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L.** (2012). Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. *Proceedings of the National Academy of Sciences*, 109(29), 11663–11668. https://doi.org/10.1073/pnas.1205073109
    - Mechanism of avibactam action against TEM-1.

11. **Hecker, S. J., Reddy, K. R., Totrov, M., Hirst, G. C., Lomovskaya, O., Griffith, D. C., King, P., Tsivkovski, R., Sun, D., Sabet, M., Tarazi, Z., Clifton, M. C., Atkins, K., Raymond, A., Potts, K. T., Abendroth, J., Boyer, S. H., Lout, J. S., Morgan, E. E., Durso, S., & Dudley, M. N.** (2015). Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. *Journal of Medicinal Chemistry*, 58(9), 3682–3692. https://doi.org/10.1021/acs.jmedchem.5b00127
    - Development of vaborbactam.

12. **Livermore, D. M.** (1995). β-Lactamases in laboratory and clinical resistance. *Clinical Microbiology Reviews*, 8(4), 557–584. https://doi.org/10.1128/CMR.8.4.557
    - Clinical impact of TEM-1 and ESBLs.

13. **Paterson, D. L., & Bonomo, R. A.** (2005). Extended-spectrum β-lactamases: A clinical update. *Clinical Microbiology Reviews*, 18(4), 657–686. https://doi.org/10.1128/CMR.18.4.657-686.2005
    - Clinical management of ESBL infections.

14. **Salverda, M. L., De Visser, J. A., & Barlow, M.** (2010). Natural evolution of TEM-1 β-lactamase: Experimental reconstruction and clinical relevance. *FEMS Microbiology Reviews*, 34(6), 1015–1036. https://doi.org/10.1111/j.1574-6976.2010.00222.x
    - Evolutionary dynamics of TEM-1.

15. **Zapun, A., Contreras-Martel, C., & Vernet, T.** (2008). Penicillin-binding proteins and β-lactam resistance. *FEMS Microbiology Reviews*, 32(2), 361–385. https://doi.org/10.1111/j.1574-6976.2007.00095.x
    - Interaction of β-lactams with PBPs and resistance mechanisms.

---

## Conclusion

P36504 (TEM-1 β-lactamase) is a paradigmatic enzyme in the field of antimicrobial resistance. Its simple structure belies a complex evolutionary history that has produced a vast array of clinically significant variants. Understanding its genomic context, structural biology, and biochemical mechanism is essential for the development of novel inhibitors and the clinical management of resistant infections. As the global burden of AMR continues to rise, TEM-1 remains a critical target for both therapeutic intervention and diagnostic surveillance. The integration of structural biology, genomics, and clinical microbiology will be paramount in combating this enduring threat.

<div data-calculator="cfu"></div>